Online inquiry

IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10959MR)

This product GTTS-WQ10959MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A&IL17F gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_002190.3; NM_052872.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605; 112744
UniProt ID Q16552; Q96PD4
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A&IL17F, MCAF-5352A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10959MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2283MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ15202MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA TA-650
GTTS-WQ10230MR IVTScrip™ mRNA-Anti-RHD, LFB-R593(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LFB-R593
GTTS-WQ4224MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ13945MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ4017MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ2760MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ13010MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW